The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The move is expected to cause a “near-term stock out of Bicillin L-A,” Pfizer said in its statement, with the drugmaker now ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

As advances in artificial intelligence technology continue to offer enticing benefits to industries across the board, pharma ...

Back in May, Bain and Botanic spent $26 million to acquire the property from Fujifilm Recording Media. The 15-acre site will ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...